Patents by Inventor Nigel MCCRACKEN

Nigel MCCRACKEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
    Patent number: 12144818
    Abstract: Methods of administering immunoconjugates that bind to CD37 are provided. The methods comprise administering an anti-CD37 immunoconjugate, optionally in combination with an anti-CD20 therapy, to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: November 19, 2024
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Elisabeth Rouits, Nigel Mccracken
  • ANTI-CD37 IMMUNOCONJUGATE DOSING REGIMENS
    Publication number: 20210196835
    Abstract: Methods of administering immunoconjugates that bind to CD37 are provided. The methods comprise administering an anti-CD37 immunoconjugate, optionally in combination with an anti-CD20 therapy, to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.
    Type: Application
    Filed: May 29, 2019
    Publication date: July 1, 2021
    Inventors: Elisabeth ROUITS, Nigel MCCRACKEN